within the quickly evolving field of oncology study, accurate and productive mutation screening is very important for acquiring specific therapies. The KRAS companies Platform plays a pivotal function On this landscape by featuring in depth solutions for KRAS mutation profiling and Assessment. KRAS mutations, located in about 95% of RAS-connected o